(NASDAQ: INMB) Inmune Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Inmune Bio's earnings in 2025 is -$40,796,000.On average, 1 Wall Street analyst forecast INMB's earnings for 2025 to be -$36,904,499, with the lowest INMB earnings forecast at -$36,904,499, and the highest INMB earnings forecast at -$36,904,499. On average, 1 Wall Street analyst forecast INMB's earnings for 2026 to be -$43,403,405, with the lowest INMB earnings forecast at -$43,403,405, and the highest INMB earnings forecast at -$43,403,405.
In 2027, INMB is forecast to generate -$38,297,122 in earnings, with the lowest earnings forecast at -$38,297,122 and the highest earnings forecast at -$38,297,122.